Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis DOI Creative Commons

Y. Liu,

Jianlin Long,

Huan Deng

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 27, 2025

Background Neoadjuvant immune checkpoint inhibitors (ICIs) have emerged as a promising treatment strategy for resectable non-small cell lung cancer (NSCLC). However, optimal combination strategies, cycles, and predictive indicators long-term outcomes remain unclear. This study aimed to evaluate the efficacy of various neoadjuvant ICI-based therapies in NSCLC, identify cycles immunochemotherapy, assess prognostic value pathological complete response (pCR) major (MPR) event-free survival (EFS). Methods A systematic literature search was conducted PubMed, EMBASE, Cochrane CENTRAL, Web Science, including studies published up October 2024. Bayesian models were used analyze different combinations, impact immunochemotherapy on MPR pCR, examine pCR EFS. Results Data from 34 included, consisting 32 single-arm (reported 26 papers) 8 RCTs, involving 4,593 patients. Immunochemotherapy combined with anti-angiogenesis agents most effective strategy, significantly improving both pCR. No significant improvement observed when number exceeded 3 cycles. Both strong predictors showed stronger negative correlation event risk compared log (HR) -2.110 (95% CI: -4.150, -0.071) MPR, -1.665 -2.419, -0.992) Conclusion appears be highly NSCLC. Three demonstrated this study. are valuable EFS, showing value. These findings offer important insights optimizing strategies informing clinical decision-making Systematic review registration PROSPERO, identifier CRD42024592346.

Язык: Английский

Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis DOI Creative Commons
Francisco Cézar Aquino de Moraes, Anna Luíza Soares de Oliveira Rodrigues, Eric Pasqualotto

и другие.

Clinical & Translational Oncology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 11, 2025

Язык: Английский

Процитировано

0
Impact of Helicobacter pylori infection status on outcomes among patients with gastric cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis DOI
Francisco Cézar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Francinny Alves Kelly

и другие.

Microbial Pathogenesis, Год журнала: 2025, Номер unknown, С. 107407 - 107407

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: a systematic review and meta-analysis DOI Creative Commons
Shuya Zhao,

Zhenzhou Lü,

Fangmin Zhao

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 21, 2025

Background Probiotics have been demonstrated to exert a potential clinical enhancing effect in cancer patients receiving immune checkpoint inhibitors (ICIs), while antibiotics detrimental impact. Prior meta-analysis papers substantial limitations and are devoid of recent published studies. Therefore, this study aimed perform an updated and, for the first time, assess whether probiotics can restore damage immunotherapy. Methods A comprehensive literature search was conducted three English databases Chinese with cutoff date August 11, 2024. The methodological quality studies evaluated using Newcastle-Ottawa Quality Assessment Scale (NOS) or Revised Cochrane risk-of-bias tool (RoB 2). Engauge Digitizer v12.1 employed extract hazard ratios (HRs) 95% confidence interval (CI) survival outcomes when these data were not explicitly provided manuscripts. Meta-analysis Stata 14 software. Results sample comprised eight retrospective four prospective studies, involving total 3,142 participants. findings indicate that significantly prolong overall (OS) (I 2 = 31.2%; HR=0.58, CI: 0.46-0.73, p < 0.001) progression-free (PFS) 65.2%; HR=0.66, 0.54-0.81, ICIs, enhance objective response rate (ORR) 33.5%; OR=1.75, 1.27-2.40, disease control (DCR) 50.0%; OR=1.93, 1.11-3.35, 0.002). For non-small cell lung (NSCLC) exposed antibiotics, use associated superior OS 0.0%; HR=0.45, 0.34-0.59, PFS HR=0.48, 0.38-0.62, compared non-users. Subgroup differences observed regarding type (P=0.006) ethnic backgrounds (P=0.011) OS. Conclusions suggest effectively extend treated ICIs. In NSCLC, appear mitigate negative impact on immunotherapy effectiveness, which has profound significance. Nevertheless, additional large-scale, high-quality randomized controlled trials necessary further validate findings. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=579047 , identifier CRD42024579047.

Язык: Английский

Процитировано

0
Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis DOI Creative Commons

Y. Liu,

Jianlin Long,

Huan Deng

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 27, 2025

Background Neoadjuvant immune checkpoint inhibitors (ICIs) have emerged as a promising treatment strategy for resectable non-small cell lung cancer (NSCLC). However, optimal combination strategies, cycles, and predictive indicators long-term outcomes remain unclear. This study aimed to evaluate the efficacy of various neoadjuvant ICI-based therapies in NSCLC, identify cycles immunochemotherapy, assess prognostic value pathological complete response (pCR) major (MPR) event-free survival (EFS). Methods A systematic literature search was conducted PubMed, EMBASE, Cochrane CENTRAL, Web Science, including studies published up October 2024. Bayesian models were used analyze different combinations, impact immunochemotherapy on MPR pCR, examine pCR EFS. Results Data from 34 included, consisting 32 single-arm (reported 26 papers) 8 RCTs, involving 4,593 patients. Immunochemotherapy combined with anti-angiogenesis agents most effective strategy, significantly improving both pCR. No significant improvement observed when number exceeded 3 cycles. Both strong predictors showed stronger negative correlation event risk compared log (HR) -2.110 (95% CI: -4.150, -0.071) MPR, -1.665 -2.419, -0.992) Conclusion appears be highly NSCLC. Three demonstrated this study. are valuable EFS, showing value. These findings offer important insights optimizing strategies informing clinical decision-making Systematic review registration PROSPERO, identifier CRD42024592346.

Язык: Английский

Процитировано

0